Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

Model scores of the 29,894 trials active now.

Model score 37% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 19% of the time (731 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-11-11. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: long termextension studysubjectsterm safetythe long
  Phrases that lowered it: safety ofchildrenevaluate theto evaluatetablets
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 33.3% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Blinding: none (raises risk) · Design
• Sponsor's past trials: 3 (lowers risk) · Sponsor's track record
• Keywords listed: 1 (raises risk) · Design
• Drug's FAERS reports before start: 0 (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design
• Maximum age: 18 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults NCT05615220 · started 2023 · scored riskier than 18% of active trials completed
• Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents NCT04007991 · started 2019 · scored riskier than 16% of active trials completed
• Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents NCT03567291 · started 2018 · scored riskier than 40% of active trials terminated
• A Study to Explore the Effect of Sepranolone in Tourette Syndrome NCT05434546 · started 2022 · scored riskier than 12% of active trials completed
• Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder NCT01416441 · started 2011 · scored riskier than 11% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.